



Press Release |

IBA Molecular presents an all-new version of its Synthera[®] at SNM'10

Louvain-la-Neuve, Belgium, June 4th, 2010 – IBA (Ion Beam Applications S.A.) announced today, that IBA Molecular Equipment will present an all-new version of its Synthera[®] at the 2010 Society of Nuclear Medicine Annual Meeting in Salt Lake City, Utah, USA.

Synthera[®] is an automated synthesizer for the production of FDG, as well as other ¹⁸F- labelled compounds such as FCH, FLT, NaF, etc. With an installed base of more than 150 platforms worldwide, Synthera[®] has proved to be highly reliable, consistent and robust therefore ensuring highest and stable yields.

The new Synthera[®] has been improved as to provide further benefits, such as integrated HPLC-based purification system, single interface for multi-modules operation, new software with more functionalities, full remote diagnosis and maintenance... while keeping its main unique advantages: compactness, multi-runs and multi-purpose capacity.

"The Synthera[®] platform allows us to upgrade our single-product facilities, producing until recently uniquely FDG, to multiple-product centers, producing FDG, NaF and FLT, while requiring minimal investment." said Renaud Dehareng, Chief Operating Officer of IBA Pharma.

The new Synthera[®] platform will be presented during a cocktail party organized for the unveiling ceremony held on IBA booth #821 during the SNM'08 congress on June 6th at 11am.

About IBA

IBA delivers solutions of exceptional precision in the fields of cancer diagnosis and therapy. The company also provides sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT and belongs to the BelMid index.

Website: <http://www.iba-worldwide.com>.

About IBA Molecular

IBA Molecular is the only global provider of PET radiopharmaceuticals. We have leveraged our global expertise and innovation to maximize our customers' access to the most reliable radiopharmaceutical distribution network, the most advanced cyclotron solutions and the most novel research radionuclides. With our focus on Protecting, Enhancing and Saving Lives, we are committed to ensuring that our customers' ability to properly care for their patients is not compromised by their access to vital radiopharmaceuticals

Contact

IBA Molecular

Peter Leitner

Sales & Marketing Director, Cyclotron Solutions

Cell: +32 499 98 56 69

Peter.Leitner@iba-group.com